• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$0.56 -$0.02 (-3.00%)

REAL-TIME: Last trade at

Peregrine Pharmaceuticals

NASDAQ:PPHM

Jump to this page for:

Related Resources

Penn Virginia Corporation, Peregrine Pharmaceuticals Among Stocks Gapping Up Monday

5/21/2012 by FOXBusiness.com

Peregrine Pharmaceuticals, Inc. Reports Positive Top-Line Data From Bavituximab Phase II Trial

5/21/2012 by BioSpace

Peregrine Pharmaceuticals target raised to $5 from $3.30 at Roth Capital

5/21/2012 by Theflyonthewall.com

Peregrine announces positive top-line data from Bavituximab Phase II trial

5/21/2012 by Theflyonthewall.com

Peregrine Announces Positive Top-Line Data From Randomized, Double-Blind Bavituximab Phase II Trial in Second-Line Non-Small Cell Lung Cancer

5/21/2012 by Marketwire

Researchers Present Data Highlighting Potential of Peregrine's PS-Targeting Antibodies to Treat Ocular Herpes Infections and Macular Degeneration

5/10/2012 by Marketwire

Peregrine's Novel PS-Targeting Technology Platform to Be Highlighted at The New York Academy of Sciences Symposium on May 1, 2012

4/26/2012 by Marketwire

Peregrine Pharmaceuticals, Inc. Cites Clinical Data to Highlight Potential of Bavituximab

4/4/2012 by BioSpace

Peregrine provides additional Bavituxima preclinical prostate cancer data

4/4/2012 by Theflyonthewall.com

Promising Clinical Data in Breast and Liver Cancers Further Expand the Broad Therapeutic Potential of Peregrine's Bavituximab

4/4/2012 by Marketwire

AVID Bioservices Highlights Antibody Engineering, Expression and Bioassay Expertise at AACR

4/2/2012 by Marketwire

Promising Data Presented at AACR Further Support New Lung Cancer Treatment Combination as Well as Ongoing Studies of Peregrine's Bavituximab

4/2/2012 by Marketwire

Peregrine Pharmaceuticals receives notice from NASDAQ

3/28/2012 by Theflyonthewall.com

Peregrine Pharmaceuticals Announces Receipt of Notice From NASDAQ

3/28/2012 by Marketwire

Peregrine Pharmaceuticals - This quarter continued..

3/12/2012 by FutureSource.com

Roth Capital removed Peregrine Pharmaceuticals (PPHM) from its Focus List

3/12/2012 by StreetInsider.com

For Biotech, 'Fail' is Making a Big Comeback

3/12/2012 by TheStreet.com

Peregrine Pharma Falls on Lung Cancer Study Data

3/12/2012 by Pharmaceutical Processing

Peregrine Pharmaceuticals removed from Focus List at Roth Capital

3/12/2012 by Theflyonthewall.com

Peregrine Pharmaceuticals' CEO Discusses Q3 2012 Results - Earnings Call Transcript

3/9/2012 by Seeking Alpha

Peregrine Pharmaceuticals files to sell $150M in common stock, warrants

3/9/2012 by Theflyonthewall.com

Peregrine Pharma (PPHM) Reports In-Line Q3 Loss of 13c/Share

3/9/2012 by StreetInsider.com

Peregrine Pharmaceuticals sees FY12 revenue $14M-$16M, consensus $13.94M

3/9/2012 by Theflyonthewall.com

Peregrine Pharmaceuticals reports Q3 EPS (13c), consensus (13c)

3/9/2012 by Theflyonthewall.com

Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2012 Financial Results and Recent Developments

3/9/2012 by StockWatch

Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2012 Financial Results and Recent Developments

3/9/2012 by Marketwire

Peregrine Pharma Cancer Drug Unmasked by Independent Review

3/9/2012 by TheStreet.com

Peregrine Pharma reports data from Phase II front-line lung cancer trial

3/9/2012 by Theflyonthewall.com

Peregrine to Report Third Quarter Fiscal Year 2012 Financial Results After Market on March 9, 2012

3/1/2012 by Marketwire

Peregrine Announces Participation at Upcoming Investor Conferences in March

2/27/2012 by Marketwire

Avid Bioservices to Present at IBC's Antibody Development and Production Conference

2/23/2012 by Marketwire

Peregrine to Present at BIO CEO and Investor Conference on Tuesday, February 14, 2012 at 8:30 AM EST

2/9/2012 by Marketwire

Peregrine Pharmaceuticals management to meet with Roth Capital

1/27/2012 by Theflyonthewall.com

Peregrine Pharmaceuticals shares undervalued, says Roth Capital

1/23/2012 by Theflyonthewall.com

MissionIR News - Peregrine Pharmaceuticals (PPHM) Announces Preliminary Results for Phase II Hepatitis Study

12/30/2011 by PRWeb

Peregrine provides update on HCV clinical program

12/29/2011 by Theflyonthewall.com

Peregrine Provides Update on HCV Clinical Program

12/29/2011 by Marketwire

Peregrine Pharmaceuticals - Last quarter was truly remarkable for clinical pipeline

12/13/2011 by FutureSource.com

Peregrine Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

12/12/2011 by Seeking Alpha

Peregrine Pharmaceuticals Inc. Reports Operating Results (10-Q)

12/12/2011 by GuruFocus
See More Articles...